QC6352

Research published in Nature reports that DHODH, an enzyme in the pyrimidine synthesis pathway, is the key target through which the KDM4 inhibitor QC6352 acts against glioblastoma stem cells. The finding suggests the compound's anti-tumour effects may stem from DHODH inhibition rather than KDM4 blockade alone, with potential implications for treating this aggressive brain cancer.